Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor XI deficiency and its management.

P H Bolton-Maggs1

  • 1Department of Haematology, Alder Hey Children's Hospital, Liverpool, UK.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|September 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International haemovigilance: what have we learned and what do we need to do next?

Transfusion medicine (Oxford, England)·2019
Same author

A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect.

Journal of thrombosis and haemostasis : JTH·2007
Same author

Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study.

Lancet (London, England)·2002
Same author

The nontreatment of childhood ITP (or "the art of medicine consists of amusing the patient until nature cures the disease").

Seminars in thrombosis and hemostasis·2001
Same author

The diagnosis and management of hereditary spherocytosis.

Bailliere's best practice & research. Clinical haematology·2000
Same author

Idiopathic thrombocytopenic purpura.

Archives of disease in childhood·2000
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Factor XI deficiency presents a variable bleeding risk, not solely dependent on severity. Understanding this bleeding disorder is crucial for managing surgical and accidental bleeding risks.

Area of Science:

  • Hematology
  • Genetics
  • Biochemistry

Background:

  • Factor XI deficiency exhibits a more variable bleeding tendency compared to hemophilia A or B.
  • Bleeding risk in Factor XI deficiency is not strictly correlated with deficiency severity, with variability observed even among individuals with similar factor XI levels.
  • The underlying reasons for variable bleeding phenotypes in Factor XI deficiency remain incompletely understood, though genotype-phenotype correlations exist in severe cases.

Purpose of the Study:

  • To elucidate the characteristics of Factor XI deficiency.
  • To review the current understanding of Factor XI's role in coagulation.
  • To discuss management strategies and available therapies for Factor XI deficiency.

Main Methods:

  • Literature review of Factor XI deficiency.

Related Experiment Videos

  • Analysis of Factor XI's role in the revised model of blood coagulation.
  • Summary of genetic mutations and population prevalence.
  • Overview of therapeutic options and their associated risks.

    • Main Results:

    • Factor XI deficiency occurs across all racial groups, with a higher prevalence in Ashkenazi Jews due to specific mutations.
    • The discovery of thrombin's role in activating Factor XI has refined coagulation models.
    • Available therapies include fresh frozen plasma, factor XI concentrates, fibrin glue, antifibrinolytic drugs, and desmopressin, each with distinct advantages and risks.

    Conclusions:

    • Factor XI deficiency management requires careful consideration of individual patient factors and therapeutic risks, such as thrombotic events associated with factor XI concentrates in older patients.
    • Further research into fibrin glue as a treatment option is warranted.
    • Understanding the variable bleeding tendency is key for effective patient management.